Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Purchased by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. grew its position in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 396.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 165,088 shares of the company's stock after purchasing an additional 131,807 shares during the quarter. Envestnet Asset Management Inc.'s holdings in Dr. Reddy's Laboratories were worth $2,607,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Robeco Institutional Asset Management B.V. increased its stake in shares of Dr. Reddy's Laboratories by 453.8% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock valued at $180,620,000 after purchasing an additional 9,373,412 shares in the last quarter. Aikya Investment Management Ltd lifted its position in shares of Dr. Reddy's Laboratories by 416.1% during the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock valued at $88,590,000 after buying an additional 4,523,303 shares in the last quarter. Vanguard Group Inc. increased its holdings in Dr. Reddy's Laboratories by 397.2% in the 4th quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock worth $77,311,000 after acquiring an additional 3,911,404 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Dr. Reddy's Laboratories by 462.1% during the fourth quarter. JPMorgan Chase & Co. now owns 2,814,710 shares of the company's stock valued at $44,444,000 after purchasing an additional 2,313,987 shares in the last quarter. Finally, Fisher Asset Management LLC grew its position in shares of Dr. Reddy's Laboratories by 402.5% in the fourth quarter. Fisher Asset Management LLC now owns 2,468,722 shares of the company's stock valued at $38,981,000 after purchasing an additional 1,977,419 shares during the period. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Dr. Reddy's Laboratories Price Performance

Dr. Reddy's Laboratories stock traded down $0.07 during midday trading on Thursday, reaching $13.86. The company had a trading volume of 183,052 shares, compared to its average volume of 1,467,587. Dr. Reddy's Laboratories Limited has a 12-month low of $12.26 and a 12-month high of $16.89. The firm's fifty day simple moving average is $13.20 and its 200-day simple moving average is $14.19. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. The company has a market capitalization of $11.57 billion, a P/E ratio of 22.08 and a beta of 0.51.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. As a group, equities analysts anticipate that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.